Scholarlink

<p>Peritoneal metastases from colorectal cancer are associated with poor survival and limited therapeutic efficacy. To model patient-specific treatment responses, we generated patient-derived scaffolds (PDS) through tumor decellularization, preserving critical microenvironmental features for functional ex vivo analysis. PDS from 75 metastases were recellularized with HT29 cells and treated with 5-fluorouracil (5-FU), mitomycin C, or oxaliplatin. Gene expression related to proliferation, epithelial phenotype, epithelial-mesenchymal transition, and stemness was quantified and integrated into a composite treatment score to estimate the most favorable therapy for each patient. Treatment responses were influenced by both drug exposure and the patient-specific microenvironment. Importantly, subcluster distributions differed across treatment arms, supporting the concept that therapeutic response is modulated by microenvironmental context rather than being solely drug dependent. These findings were supported in a smaller validation cohort using HCT116 and DLD-1 cells recellularized into selected PDS. Treatment scoring based on HT29 cells revealed heterogeneous sensitivity patterns, with 38.7% of PDS responding best to 5-FU, 36% to mitomycin C, and 25.3% to oxaliplatin. Patients with more than two favorable treatment scores had improved disease-free survival (<i>p</i> = 0.0415). The PDS platform enables functional profiling of chemotherapy-response and may support individualized treatment strategies for colorectal cancer patients with peritoneal metastases.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Personalized chemotherapy guidance using patient-derived scaffolds from peritoneal colorectal metastases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月1日

查看全文
  • Simona Salerno,
  • André Holdfeldt,
  • Anders Ståhlberg,
  • Marianne Quiding Järbrink,
  • Göran Landberg,
  • Elinor Bexe Lindskog

摘要

Peritoneal metastases from colorectal cancer are associated with poor survival and limited therapeutic efficacy. To model patient-specific treatment responses, we generated patient-derived scaffolds (PDS) through tumor decellularization, preserving critical microenvironmental features for functional ex vivo analysis. PDS from 75 metastases were recellularized with HT29 cells and treated with 5-fluorouracil (5-FU), mitomycin C, or oxaliplatin. Gene expression related to proliferation, epithelial phenotype, epithelial-mesenchymal transition, and stemness was quantified and integrated into a composite treatment score to estimate the most favorable therapy for each patient. Treatment responses were influenced by both drug exposure and the patient-specific microenvironment. Importantly, subcluster distributions differed across treatment arms, supporting the concept that therapeutic response is modulated by microenvironmental context rather than being solely drug dependent. These findings were supported in a smaller validation cohort using HCT116 and DLD-1 cells recellularized into selected PDS. Treatment scoring based on HT29 cells revealed heterogeneous sensitivity patterns, with 38.7% of PDS responding best to 5-FU, 36% to mitomycin C, and 25.3% to oxaliplatin. Patients with more than two favorable treatment scores had improved disease-free survival (p = 0.0415). The PDS platform enables functional profiling of chemotherapy-response and may support individualized treatment strategies for colorectal cancer patients with peritoneal metastases.